ArticleFrontiers in microbiology2026
A red/blue bicolor lateral flow immunoassay for simultaneous detection of two enteroviruses based on duplex RT-LAMP.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Norovirus and human adenovirus are the main pathogens causing acute gastroenteritis (AGE) worldwide. Their highly contagious nature, significant disease burden, similar symptoms, and frequent co-infection necessitate a differential diagnostic tool to guide epidemic control and support antimicrobial stewardship by rapidly ruling out bacterial etiologies. Methods: This study developed an integrated dual reverse transcription loop-mediated isothermal amplification (RT-LAMP) and dual-color lateral flow immunoassay (LFIA) technology for rapid, sensitive, and visual synchronous detection of norovirus genogroup II (NoV GII) and human adenovirus F41 (HAdV F41) in human feces. LAMP primers for the two viruses were labeled with FAM/biotin and TAMRA/biotin, respectively. Combined with a dual-color gold nanomaterial signaling system (red AuNPs for test lines, blue AuNFs for control line), the assay allows for intuitive visual interpretation. Results: The method demonstrated good sensitivity and specificity, with detection limits of 5.8 copies/μL for NoV GII and 63 copies/μL for HAdV F41, and no cross-reactivity with common non-target pathogens. The entire reaction process requires only a constant temperature of 65°C and can be completed within 45 min. Discussion: The clear dual-color interpretation system, user-friendly operation, and excellent performance make it a highly promising tool for first-line screening and point-of-care diagnosis of AGE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.